Design of Coelenterazine Analogue to Reveal Bioluminescent Reaction of Human Serum Albumin by Nishihara, Ryo et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books










Ryo Nishihara, Kazuki Niwa,Tatsunosuke Tomita
and Ryoji Kurita
Abstract
This chapter describes the design of an imidazopyrazinone-type luciferin named
as HuLumino1 by us and investigation of its luminescence properties. This luciferin
was designed to generate bioluminescence by human serum albumin (HSA) rather
than by luciferase derived from luminous organisms. HuLumino1 was developed by
modifying a methoxy-terminated alkyl chain to the C-6 position and eliminating a
benzyl group at the C-8 position of coelenterazine. To clarify the basis of light
emission by HSA, the detailed kinetic properties of the HuLumino1/HSA pair were
investigated using a calibrated luminometer. The enzymatic oxidation of
HuLumino1 was observed only in the presence of HSA. Results of HSA quantifica-
tion experiments using HuLumino1 agreed with less than 5% differences with those
of enzyme-linked immunosorbent assays, suggesting HuLumino1 could be used for
quantitative analysis of HSA levels in serum samples without any pretreatments.
These results demonstrate the advantages of the coelenterazine analogue as a bio-
luminescence reagent to detect non-labeled proteins, which generally do not func-
tion as enzymes.
Keywords: Bioluminescence, Coelenterazine, Luciferin, Luciferase, Human serum
albumin, Quantum yield, Enzyme-linked immunosorbent assay
1. Introduction
Luminous organisms, such as fireflies, Gaussia princeps, Oplophorus gracilirostris,
and sea pansy Renilla reniformis, generate bioluminescence (BL), which is the light
emission in the absence of external energy sources [1, 2]. In the core of BL, an
enzymatic reaction occurs involving a bioluminescent substrate (luciferin) and
enzyme (luciferase). In general, the enzymatic luminescence reaction proceeds
between a specific luciferin-luciferase pair to allow for highly sensitive and specific
detection/imaging of diverse molecular events in living subjects [2–4].
However, in some cases, bioluminescent or chemiluminescent substrates may
induce enzymatic luminescence activity of non-bioluminescence enzymes. For
example, CycLuc2, a synthetic analog of firefly luciferin, can be catalyzed to emit
light by long-chain fatty acid acyl-CoA synthetase found in non-luminous insects
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[5–7]. In addition, the heme-containing enzyme myeloperoxidase, which is abun-
dantly expressed in neutrophils and monocytes, can catalyze the luminescence
reaction of xenobiotic luminol [8, 9]. These reports suggested that the introduction
of appropriate exogenous luminescent substrates reveals luminous activity of non-
bioluminescence enzymes, which can significantly differ from the conventional
function of the enzyme and has potential for use in quantitative analysis of enzymes
without any labeling procedures, including transgene introduction of luciferase
from luminous organisms. Here, we describe the design and bioluminescence char-
acterization of a luciferin analogue which was selectively catalyzed to exhibit bio-
luminescence by human serum albumin (HSA) [10]. Serum albumins perform
various physiological functions; they maintain colloid osmotic blood pressure and
transport several exogenous and endogenous molecules. However, they are not
categorized in the list of EC number, indicating they are not considered typical
enzymes. The bioluminescence system of HSA with the luciferin analogue synthe-
sized by us is novel and different from the conventional luciferin-luciferase reaction
systems.
2. Design of coelenterazine analogue
2.1 Coelenterazine analogue with HSA-specific bioluminescence
Most luciferases from luminous marine organisms use coelenterazine (CTZ) as
their luciferin to form coelenteramide in an excited state, with emission ranging
from blue to green at approximately 400–500 nm (Figure 1) [11, 12]. CTZ is
oxidized by bovine serum albumin (BSA) in addition to luciferase, and this has been
considered as nonspecific reaction mainly occurs because of a simple luminescence
reaction that requires only an oxygen molecule [1] (Figure 1).
The emission ability of CTZ is derived from the imidazopyrazinone ring, and the
chemical structure of sidechains at the C-2, C-6, and C-8 position of the
imidazopyrazinone core significantly affect enzyme recognition. For example,
Cypridina luciferase oxidizes only Cypridina luciferin, which contains a basic gua-
nidine moiety at the C-8 position of the imidazopyrazinone ring, not CTZ
(Figure 2) [13]. A mutant Oplophorus luciferase (NanoLuc) uses furimazine rather
than CTZ, and is known as a versatile reporter of BL (Figure 2) [14]. Thus, each
bioluminescence probe has been individually developed with an imidazopyrazinone
analogue that is suitable for the geometry of the active site in the pocket of mutant
luciferase. We also reported that RLuc8.6-535SG, a mutant R. reniformis luciferase,
utilizes BottleBlue2.3 (BBlue2.3), a CTZA that can permeate the cell membrane and
emits bright visible luminescence suitable for deep-tissue imaging of cancer cells
in vivo (Figure 3a) [15].
To clarify the potential enzymatic luminescence activity of human proteins, we
focused on HSA, which accounts for approximately 65% of serum proteins in the
human body [16]. This abundant protein is involved in a wide variety of
Figure 1.
Chemical reaction of coelenterazine (CTZ)-dependent bioluminescence. The imidazopyrazinone structure and
modifiable substituent are highlighted in red and blue, respectively.
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physiological functions, such as maintaining osmotic pressure, buffering blood pH
levels, and carrying ligands including hormones, amino acids, and fatty acids
[17, 18]. In addition, HSA and some ligand complexes often possess enzymatic
activities, such as Kemp elimination and hydrolysis of esters because of their unique
Figure 2.
Chemical structures of imidazopyrazinone-based analogues.
Figure 3.
Chemical structures of coelenterazine analogues (CTZAs) upon (a) C-2 and/or C-6 substitution.
(b) Luminescence intensities obtained with serum albumin (0.1 mg/mL).
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ability to bind small hydrophobic molecules in some cavities; however, the potential
enzymatic activities remain unclear [17, 19].
First, to obtain a rational luciferin with an imidazopyrazinone core for HSA-
specific BL, we assayed CTZ and previously reported 18 CTZAs named as Bottle
Blue (BBlue), where the p-hydroxy phenyl group at the C-6 position of CTZ was
modified by alkylation (Figure 3), with serum albumins (fatty acid free HSA and
BSA). In this chapter, except for in Section 2.2, luminescence measurements were
performed using luminometers (GloMax20/20 Luminometer or GloMax Explorer
Multimode Microplate Reader) manufactured by Promega (Madison, WI, USA).
Next, BBlue2.3, a CTZA with a methoxy-terminated alkyl linker chain of three
methylene units at the C-6 position, exhibited the brightest emission, which pro-
duced 16.6-fold higher luminescence when combined with HSA (i.e. BBlue2.3/HSA
pair) compared to that of the CTZ/HSA pair (Figure 3).
Based on these results, we predicted that elimination of the benzyl group at the
C-8 position of BBlue2.3 would relieve its steric hindrance with key amino acids in
the substrate binding site of HSA and enhance the enzymatic luminescence reaction
of HSA. We then designed and synthesized a novel CTZA, named as Human
Luminophore 1 (HuLumino1) based on the synthetic procedures of BBlue2.3 [15]
and an array of 5 CTZAs containing known analogues [20] to investigate the effect
of substitution at the C-2, C-6, and C-8 positions of CTZ on serum albumin-
dependent luminescence (Figure 4b–d). Moreover, the luminescence of
Figure 4.
Chemical structures of coelenterazine analogues (CTZAs) upon (a) C-2, C-6, and C-8 substitutions, (b) HSA-
specific substitution, (c) C-2 and C-6 substitution, and (d) C-2 or C-6 substitution. (e) Luminescence from
serum albumins (0.1 or 1 mg/mL) treated with the indicated substrate (10 μM); error bars represent the




commercially available CTZAs (DeepBlueC and MCLA) was compared with the
synthesized CTZAs when fatty acid free HSA and BSA were added (Figure 4e).
Although the autoluminescence levels in PB buffer of HuLumino1 was similar to
that of CTZ, only HuLumino1 displayed significantly enhanced luminescence
dependent on HSA (but not BSA containing fatty acid) concentrations, as indicated
by the 14.1-fold higher emission compared with that of the BBlue2.3/HSA pair.
Furthermore, the luminescence intensity of the HuLumino1/HSA pair was found to
be 718-fold higher than that of the CTZ/BSA pair, which has been reported to
produce luminescence [11, 12]. The HuLumino1/HSA pair exhibited flash-type
luminescence with a peak wavelength of 432 nm. (Figure 4f). Unexpectedly,
HuLumino1 selectively activated HSA by recognizing the subtle conformational
difference in the substrate binding site, although the overall sequence homology
between HSA and BSA is 75.6%.
These results suggest “luciferase” activity of HSA catalyzes the enzymatic lumi-
nescence reaction of CTZAs to produce “bioluminescence”.
2.2 Quantitative evaluation of luminescence intensity
To characterize the enzymatic luminescence reaction with HSA, the biolumi-
nescence intensity of CTZAs and HSA pairs was quantitatively evaluated. Biolumi-
nescence intensity is generally determined by several reaction factors including the
bioluminescence quantum yield φBLð Þ of luciferin, turnover number (kcat), and
active luciferase concentration. Kinetic parameters were determined using a
custom-built luminometer with a photomultiplier tube (PMT) (H11890–01; Hama-
matsu Photonics, Japan), and its absolute responsibility for total number of emitted
photons in the instrument was calibrated for luminescence spectrum of each
luciferin-luciferase pair [21, 22]. The absolute responsibility of the luminometer for
the CTZ-utilizing bioluminescent system was determined as described previously
[21]. The φBL values were calculated from the total number of emitted photons and
total number of reacted luciferin molecules. To integrate all photons derived from
the enzymatic reaction, the number of photons was monitored using the
luminometer from before initiating the reaction to until the reaction was completed.
The reaction was initiating by injection of fatty acid-free HSA PB solution (100 μg/
mL or 10 mg/mL) into the preinstalled luciferin PB solution (20 nM) in the
luminometer.
The Michaelis–Menten constant (Km) of luciferin was calculated from
Lineweaver-Burk plots constructed using a standard method. The catalytic constant
(kcat), which is the turnover number of the reaction for luciferin by a single
luciferase molecule per second, was calculated from the φBL value and maximum
velocity (Vmax) determined from the Lineweaver-Burk plots.
The apparent Km of the HuLumino1/HSA pair was 4.3 μM, which was compara-
ble to that of the NanoLuc system [23]. In contrast, the kcat value of the NanoLuc
system was 294-fold higher than that of the HuLumino1/HSA pair, and the catalytic
efficiency of the luminescence reaction by HSA was lower than that of conventional
luciferase [24]. However, in the luminescence system with HSA, HuLumino1
displayed a slightly higher Km value than CTZA-1, but its kcat value was approxi-
mately 3-fold higher (Table 1), resulting in 4.2-fold stronger light emission than
that of CTZA-1 (Figure 4e). For luciferin with high enzyme affinity (e.g., CTZA
1), oxyluciferin, a product of the BL reaction, appears to competitively inhibit the
luminescence reaction [25]. Moreover, HuLumino1 showed an enzyme affinity and
bioluminescence quantum yield φBLð Þ of more than 5- and 100-fold higher than
those of CTZ, respectively. The detailed luminescent profiles suggest that the
structural properties of the alkyl linker chain modified at the C-6 position of the
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imidazopyrazinone core contribute to the efficient HSA-catalyzed emission reac-
tion. Although the catalytic efficiency of HuLumino1/HSA is much lower than that
of the NanoLuc system, HuLumino1 is a luciferin that is relatively more suitable for
HSA than other existing luminescent substrates.
2.3 Enzymatic reaction site of HSA
The crystal structure of HSA, with binding to a variety of drugs, clarified the two
principal drug binding sites in different subdomains (site 1 in subdomain IIA and site
2 in subdomain IIIA) [26, 27]. To investigate the luminescent reaction site between
HSA and HuLumino1, a competitive assay was conducted with two site-specific HSA
drugs (warfarin-site1 and ibuprofen-site2) [27]. Fatty acid free HSA PB solution was
pre-treated with the drugs (0–100 μM) to fill binding site 1 or 2 before adding
HuLumino1. The luminescence of HuLumino1 was negligibly low in the presence of
HSA-ibuprofen complex (Figure 5a). In contrast, HuLumino1 exhibited efficient
luminescence with the HSA-warfarin complex, indicating that HuLumino1 selectivity
binds to the site 2 cavity of HSA. In detailed analysis of the inhibitory kinetics,
Lineweaver-Burk plots displayed that ibuprofen competitively inhibited the binding
of HuLumino1 to HSA (Ki of ibuprofen was 6.3 nM) (Figure 5b). Therefore, the
enzymatic reaction site of HuLumino1 was experimentally determined to be binding
site 2. Next, docking simulation with the Molecular Operating Environment software
package was carried out to predict the binding poses. The simulation displayed the
specific binding of HuLumino1 to the hydrophobic cavity of site 2 by interacting with
several amino acids including R410, K414, and L453 (Figure 5c–e). Particularly,
R410, a key amino acid residue in the esterase activity of HSA [17], is also involved in
the luminescence reaction (Figure 5e).
Next, to investigate the effect of the steric structure of HSA on luminescence,
HSA pretreated with 10 M guanidine hydrochloride, a reagent commonly used to
induce denaturation of the α-helix structure of proteins [28], was prepared, and the
luminescence of HuLumino1 was extremely low in the presence of denatured HSA
(data not shown). Therefore, the enzymatic reaction of HuLumino 1 depends on the
microenvironment and steric structure such as binding site 2 constructed by the
folding structure of HSA. These results suggest that emission of HuLumino1/HSA is
not a non-specific chemiluminescence commonly found in other
imidazopyrazinone compounds.
2.4 Bioluminescent assay for HSA
Low levels of HSA in the serum (<35 mg/mL) are biomarkers of several diseases








CTZ/HSA 0.32  0.03 25.3  5.2 2.75  0.3
HuLumino1/HSA 30.9  3.1 4.28  1.24 0.30  0.06
CTZA-4/HSA 42.2  9.1 2.46  0.40 0.11  0.09
a–cErrors represent standard error of the mean values for triplicate experiments.
bMichaelis-Menten constant (Km) values were determined by Lineweaver-Burk plots via measurements of initial rates
of light emission over a range 0.5 to 20 μM.
cTurnover rate (kcat) values were calculated by dividing maximum velocity (Vmax) by the φBL. The Vmax were
determined by Lineweaver-Burk plots.
Table 1.
Luminescent profiles of CTZ and its analogues with HSA.
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evaluated using the colorimetric bromocresol green assay or ELISA. Both can pro-
vide a reliable assessment of albumin but require sample preparation and processing
time (e.g. 3 h for ELISA) [30]. Therefore, an assay for the simple, accurate and
Figure 5.
(a) Luminescence response in the presence (I) vs. absence (I0) of the binding drug concentration (0–100 μM).
(b) Lineweaver-Burk plot indicating competitive inhibition by ibuprofen. V0 is defined as the luminescence
intensity over the initial 30 s and [S] is the substrate concentration. The concentrations of ibuprofen were 1 nM
(square) and 5 nM (triangle). Open circles indicate negative controls with no ibuprofen. (c) Ligand-binding
site 2 of HSA with HuLumino1 as posed by the molecular operating environment software (d) magnified view
of binding site 2. The ligand binding site in the blue region indicates the presence of the hydrophobic
environment. (e) Predicted interaction between HuLumino1 and HSA.
7
Design of Coelenterazine Analogue to Reveal Bioluminescent Reaction of Human Serum Albumin
DOI: http://dx.doi.org/10.5772/intechopen.97232
rapid detection of HSA in the serum should be developed for clinical diagnosis. We
demonstrated that the BL assay can be used to evaluate HSA based on the enzymatic
luminescence reaction of HuLumino1. Regarding the selectivity of the reaction of
HuLumino1, no reactivity with other proteins (BSA, β-galactosidase,β-lactoglobu-
lin, catalase, α-chymotrypsinogen, hemoglobin, human IgG, porcine lipase, papain,
pepsin, trypsin, γ-globulin, carbonic anhydrase, concanavalin A, glucosidase, his-
tone, myoglobin, and RNase, 0.1 mg/mL) was observed, and only HSA led to
distinct luminescence enhancement (Figure 6a). Although the coexistence of most
proteins did not affect the enzymatic reaction of the HSA/Hulumino1 pair, a slight
decrease in luminescence was observed in the presence of some proteins (data not
shown). This indicates that HuLumino1 nonspecifically binds to other proteins but
does not exhibit BL. Hence, HuLumino1 can be used to detect HSA without inter-
ference from other proteins, as it exhibited excellent selectivity for HSA even in a
complicated biological system. The luminescence of HuLumino1 was enhanced in
an HSA concentration-dependent manner and exhibited a constant intensity at HSA
concentrations above 10 mg/mL (Figure 6b). A linear increase in luminescence,
within the spiked HSA concentration range of 0–0.1 mg/mL in PBS-diluted serum,
resulted in a detection limit of 8.6 μg/mL for HSA, which was comparable to the
standard detection limit of HSA in physiological systems (Figure 6c) [31].
Finally, two HSA assays, including our developed BL-based assay and ELISA,
were performed to evaluate human serum from male AB plasma. The HSA levels
calculated with HuLumino1 agreed well with those estimated by ELISA within 5%
error. The spike and recovery tests also showed results within the margin of 7%
Figure 6.
(a) Variation in luminescence of HuLumino1 (10 μM) in the presence of proteins (0.1 mg/mL); error bars
represent the standard deviations of three measurements. (b) Luminescence intensity of HuLumino1 (20 μM)
containing various concentrations of HSA (0–17 mg/mL) in PBS and (c) HSA (0–17 mg/mL) in PBS-diluted
plasma (100-fold, pH 7.4).
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error (Table 2). Therefore, the BL-based HSA assay showed analytical capability
with high sensitivity and could detect HSA within 10 min including the sample
preparation and measurement times. In addition, we detected the expression of
recombinant HSA in living COS-1 cells (data not shown), indicating that
HuLumino1 can be used in molecular biology studies and in biomedical
applications.
We designed and synthesized the first luciferin (HuLumino1), an analogue with
C-6 and C-8 modification of CTZ, which exhibited bioluminescence with HSA.
HuLumino1 rapidly detected HSA with high sensitivity and specificity, even in real
human plasma containing various interfering biomolecules. Detailed kinetic inves-
tigation of the enzymatic reaction clarified the enzyme recognition of HuLumino1
from HSA drug binding site 2, resulting a highly selective reaction and revealing a
reaction with both native HSA and recombinant HSA expressed in COS-1 cells.
Therefore, the BL-based assay with HuLumino1, either used alone or coupled with
ELISA, can be used for the early diagnosis of HSA-related diseases, enabling accu-
rate and rapid detection of HSA in serum samples without pre-treatment. The
information obtained through detailed investigation of the HuLumino1/HSA pair
may be extended to protein assays based on a luminescent reaction without
genetically engineered luciferases.
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(mg/mL)





0 39.0  3.1 41.0  3.6 95.2
1 44.5  0.5 ND 106.1
2.5 45.2  0.5 ND 104.1
ND: Not Determined.
aConditions: HuLumino1 (20 μM) in PBS-diluted serum (1000-fold, 10 mM, pH 7.4).
Table 2.
Assay of HSA in human serum.
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